Using CYTAG® SuperCGH Labeling Kit for the Analysis of FFPE Oncological Samples by CGH

INTRODUCTION

Microarray-based comparative genomic hybridization (array CGH) is a fast genome-wide screening tool for the high resolution detection of chromosomal anomalies in the form of copy number variations (CNVs).

In the oncology field, aCGH represents a valuable prognostic tool. It allows the identification of the genetic alterations characterizing the tumor of a specific patient, giving precious information on its evolution, and facilitating the choice of the best treatment. However, biopsies are usually preserved in a formalin-fixed paraffin-embedded (FFPE) form. Both the quantity and the quality of the DNA extracted from FFPE tissues are variable, making the analysis by CGH of these specimens challenging.

The cytogenetic service at the University Hospital of Limoges carries out hundreds of prenatal, postnatal, and oncological CGH tests per year on a variety of specimens, including amniotic fluid, blood, and FFPE tissues. The objective of this study was to test Enzo’s CYTAG® SuperCGH Labeling Kit with DNA extracted from oncological FFPE tissues, identifying the best labeling protocol to optimize the results

Download this Application Note